Clicky

G1 Therapeutics, Inc.(GTHX)

Description: G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.


Keywords: Cancer Biopharmaceutical Drugs Treatment Of Cancer Breast Cancer Hormones Treatment Of Breast Cancer Protein Kinase Inhibitor Her2/Neu Her2 Estrogen Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Fulvestrant

Home Page: www.g1therapeutics.com

GTHX Technical Analysis

700 Park Offices Drive
Research Triangle Park, NC 27709
United States
Phone: 919 213 9835


Officers

Name Title
Mr. John E. Bailey Jr. CEO, Pres & Director
Ms. Jennifer K. Moses CPA Chief Financial Officer
Dr. Mark A. Velleca M.D., Ph.D. Sr. Advisor & Director
Dr. Rajesh K. Malik Ch.B., M.B., M.D. Chief Medical Officer and Sr. VP of R&D
Mr. Mark Avagliano Chief Bus. Officer
Mr. Andrew Perry Chief Commercial Officer
Mr. Terry L. Murdock Chief Operating Officer
Mr. Alexander D. Smith M.S. VP of Technical Operations
Dr. Jay C. Strum Ph.D. Chief Scientific Officer
Mr. William C. Roberts VP of Investor Relations & Corp. Communications

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 7.036
Price-to-Sales TTM: 6.4606
IPO Date: 2017-05-17
Fiscal Year End: December
Full Time Employees: 148
Back to stocks